All In Biotech

Drug Trial Radar · NCT02991118

Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk

A Long-term, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk Not Adequately Controlled by Their Lipid-Modifying Therapy

Last checked: Nov 20, 2026Latest source record: Apr 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 779 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

779

Actual

Start

Nov 18, 2016

Primary completion

Aug 22, 2018

Study completion Aug 22, 2018

Sponsor

Lead sponsor
Esperion Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 13, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to see if bemedoic acid (ETC-1002) is effective versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol not adequately controlled by their current therapy.

Conditions

  • Hypercholesterolemia
  • Atherosclerotic Cardiovascular Disease

Interventions

  • bempedoic acidDrug

    bempedoic acid 180 mg tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)

  • placeboDrug

    Matching placebo tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)Time frame: Baseline; Week 12

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Clearwater, Florida

  • Site not named

    Georgetown, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.